EU/3/10/846

About

On 23 February 2011, orphan designation (EU/3/10/846) was granted by the European Commission to BTG plc, United Kingdom, for paclitaxel (aqueous gel) for the treatment of oesophagus carcinoma.

Key facts

Active substance
paclitaxel
Disease / condition
Treatment of oesophagus carcinoma
Date of first decision
23/02/2011
Outcome
Positive
EU designation number
EU/3/10/846

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

BTG plc
5 Fleet Place
London EC4M 7RD
United Kingdom
Tel. + 44 (0)20 7575 0000
Fax + 44 (0)20 7575 0010
E-mail: info@btgplc.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating